...
| Drawio |
|---|
| border | true |
|---|
| |
|---|
| diagramName | General Pattern for Contextualized Roles |
|---|
| simpleViewer | false |
|---|
| width | |
|---|
| links | auto |
|---|
| tbstyle | top |
|---|
| diagramDisplayName | General pattern for contextualized roles |
|---|
| lbox | true |
|---|
| diagramWidth | 701661 |
|---|
| revision | 1718 |
|---|
|
Diagram 1: General pattern for contextualized roles.
...
| Drawio |
|---|
| border | true |
|---|
| diagramName | General Pattern for Contextualized Roles - Moiety Role |
|---|
| simpleViewer | false | width |
|---|
| links | auto |
|---|
| tbstyle | top |
|---|
| diagramDisplayName | Amlodipine as the active moiety for Amlodipine bezylate in a regulatory context |
|---|
| lbox | true |
|---|
| diagramWidth | 601 |
|---|
| revision | 7 |
|---|
|
...
| Drawio |
|---|
| border | true |
|---|
| diagramName | Moiety Role - Aripiprazole - FDA Patent Exclusivity - simplified |
|---|
| simpleViewer | false | width |
|---|
| links | auto |
|---|
| tbstyle | top |
|---|
| diagramDisplayName | N-hydroxymethyl aripiprazole as the active moiety for Aripiprazole lauroxil in a FDA patent exclusivity regulatory context |
|---|
| lbox | true |
|---|
| diagramWidth | 883 |
|---|
| revision | 3 |
|---|
|
...
| Drawio |
|---|
| border | true |
|---|
| diagramName | Moiety Role - Aripiprazole - FDA GSRS context |
|---|
| simpleViewer | false | width |
|---|
| links | auto |
|---|
| tbstyle | top |
|---|
| diagramDisplayName | Aripiprazole as the active moiety for Aripiprazole lauroxil in a FDA GSRS context |
|---|
| lbox | true |
|---|
| diagramWidth | 782 |
|---|
| revision | 2 |
|---|
|
...
| Drawio |
|---|
| border | true |
|---|
| diagramName | Copy of Moiety Role - Aripiprazole - FDA GSRS context |
|---|
| simpleViewer | false | width |
|---|
| links | auto |
|---|
| tbstyle | top |
|---|
| diagramDisplayName | Aripiprazole lauroxil as the active moiety for Aripiprazole lauroxil in a USP salt policy context |
|---|
| lbox | true |
|---|
| diagramWidth | 791 |
|---|
| revision | 2 |
|---|
|
...